CN104258203A - Traditional Chinese medicine combination for preventing and curing leucopenia caused by radiotherapy - Google Patents

Traditional Chinese medicine combination for preventing and curing leucopenia caused by radiotherapy Download PDF

Info

Publication number
CN104258203A
CN104258203A CN201410563172.XA CN201410563172A CN104258203A CN 104258203 A CN104258203 A CN 104258203A CN 201410563172 A CN201410563172 A CN 201410563172A CN 104258203 A CN104258203 A CN 104258203A
Authority
CN
China
Prior art keywords
parts
radix
chinese medicine
rhizoma
radiotherapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201410563172.XA
Other languages
Chinese (zh)
Inventor
陈洁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201410563172.XA priority Critical patent/CN104258203A/en
Publication of CN104258203A publication Critical patent/CN104258203A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/41—Crassulaceae (Stonecrop family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A61K36/074—Ganoderma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A61K36/076—Poria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/232—Angelica
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/236—Ligusticum (licorice-root)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/284—Atractylodes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/34—Campanulaceae (Bellflower family)
    • A61K36/344—Codonopsis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/481—Astragalus (milkvetch)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484—Glycyrrhiza (licorice)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/80—Scrophulariaceae (Figwort family)
    • A61K36/804—Rehmannia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A61K36/815—Lycium (desert-thorn)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
    • A61K36/8888—Pinellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8969—Polygonatum (Solomon's seal)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A61K36/8998—Hordeum (barley)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention discloses a traditional Chinese medicine combination for preventing and curing leucopenia caused by radiotherapy. The traditional Chinese medicine combination is prepared by the following traditional Chinese medicine materials in parts by weight: 2 to 3 parts of rhodiola root, 1 to 2 parts of ginseng, 2 to 3 parts of astragalus root, 1 to 2 parts of sun-dried ginseng, 1 to 2 parts of atractylodes macrocephala, 2 to 3 parts of indian bread, 1 to2 parts of prepared licorice root, 1 to 2 parts of Chinese angelica root, 1 to 2 parts of ligusticum chuanxiong hort, 1 to 2 parts of ganoderma lucidum, 1 to2 parts of fox glove, 1 to 2 parts ass-hide glue, 2 to 3 parts of wolferry fruit, 2 to 3 parts of siberian solomoseal rhizome, 1 to 2 parts of chickens gizzard-skin, 1 to 2 parts of coloured malt, 1 to 1.5 parts of pinellia, and 1 to 1.5 parts of pilose asiabell root. The ass-hide glue can be replaced by 0.5 to 1 part of antler gelatin. The traditional Chinese medicine combination can adopt decoction, and can also be prepared into oral liquid, granules, fluid extract or wine through traditional methods. The combination is used for preventing and curing leucopenia caused by radiotherapy, and can also be applied to leucopenia caused by other reasons.

Description

One causes leukopenic Chinese medicine composition for preventing and treating radiotherapy
 
Technical field
The invention belongs to the field of Chinese medicines, particularly one be applicable to control radiotherapy cause leukopenic Chinese medicine composition.
Background technology
Put, radiotherapy is the large Therapeutic Method of tumor two two kinds, put, radiotherapy can cause bone marrow depression, especially common with radiotherapy.Clinically to occur the earliest with leukopenia, have impact on carrying out smoothly of radiotherapy, thus have impact on antineoplaston curative effect.According to foreign literature report, the treatment related mortality relevant with work IV degree bone marrow depression hemogram in radiotherapy can reach 4%-21%.Clinically because radiotherapy process caused by cytopenia is obstructed, result in tumor by local and control curative effect and reduce, the untoward reaction caused by breast carcinoma, tumor of head and neck, pulmonary carcinoma and tumor in upper digestive tract causes great misery to patient.Therefore radiotherapy causes myelosuppressive control to become the key improving antitumor curative effect.
The appearance of recombinant human granulocyte colony stimulating factor (G-CSF), put for solving, leukopenic problem provides sound assurance after radiotherapy, G-CSF has stimulation to GO phase cell, mainly act on a CFU-GM, promote its neutrophil proliferation to maturation, differentiation, and maintain its function and survival.It can improve marrow function rapidly, suppresses the leukocyte in patient's peripheral blood, especially neutrophil cell.But it acts on poor stability, after subcutaneous injection, be full of a large amount of korocyte in peripheral blood and bone marrow smear, numeration of leukocyte presented be doubled and redoubled, decline phenomenon at double, patient is for maintaining medication repeatedly of having to the normal course for the treatment of.G-CSF, GM-CSF treat caused by radiation bone marrow depression, although short term effect is comparatively definite, expensive, hold time short, action pathway is single, to erythrocyte and platelet curative effect undesirable.Main adverse reaction is osteodynia, and dosage improves, and incidence rate is higher.Other common adverse reactions comprise heating, headache, myalgia etc.In addition, likely stimulate some Malignant cellular growth, bone marrow reserve also may be caused not enough, and after making, radiotherapy encounters difficulties.
If other leucocyte increasing agents are as Trionyx sinensis Wiegmann liver alcohol, leucogen, flesh, adenine phosphate, carbonic acid file, SHENGBAIAN PIAN etc., can promote hemopoietic function, stimulates Leukocytopoiesis, thus leukocyte increasing.But effect is all comparatively slow, curative effect owes satisfied.Glucocorticoid is because of the side effect of itself, and it may have facilitation to some malignant tumor, limits Clinical practice.Component blood transfusion, hematopoietic stem cell transplantation or support to be used for serious bone marrow depression, but there is the danger infecting haematogenous infectious disease, the hemocyte be input in the recipient's body endogenous cause of ill rejection effect time-to-live shorter and also have promote cancerous protuberance recurrence growth may.
Therefore, how to find a kind of to hemogram minimizing determined curative effect after radiotherapy, toxicity is little, and the prevention and controls that medical treatment cost is low becomes tumor therapy clinical study hotspot.
The research of Chinese medicine after control radiotherapy in leukopenia is quite a few, from theoretic discussion to clinical research, all achieves many progress.Theory of pathogenesis is contended development, and clinical research deepens continuously, and improves constantly the leukopenic understanding of radiotherapy, and it has become one of important topic in current irradiation complication field.Chinese medicine has the advantage of tcm treatment according to syndrome differentiation and flexile treatment means, and effect is better.Compared with Western medicine, have effect steadily, the advantage such as lasting, low price, side effect be little, and the advantage and characteristic that traditional Chinese medical science wholism controls can be embodied.Promoting leukocytic while, also can improve clinical symptoms preferably, concerning tumor patient, can enhancing human body immunity power, improve the quality of living, be with a wide range of applications.
Summary of the invention
The object of the invention is, for the above-mentioned existing deficiency carrying leucocyte increasing agent, to provide the Chinese medicine composition that a kind of instant effect, good effect, cost price are low, have no side effect, for leukopenic patient after preventing and treating radiotherapy.
Of the present invention for leukopenic Chinese medicine composition after preventing and treating radiotherapy, be made up of the raw material of Chinese medicine of following weight portion: Radix Rhodiolae 2-3 part, Radix Ginseng 1-2 part, Radix Astragali 2-3 part, Radix Ginseng 1-2 part, Rhizoma Atractylodis Macrocephalae 1-2 part, Poria 2-3 part, Radix Glycyrrhizae Preparata 1-2 part, Radix Angelicae Sinensis 1-2 part, Rhizoma Chuanxiong 1-2 part, Ganoderma 1-2 part, Radix Rehmanniae Preparata 1-2 part, Colla Corii Asini 1-2 part, Fructus Lycii 2-3 part, Rhizoma Polygonati 2-3 part, Endothelium Corneum Gigeriae Galli 1-2 part, Fructus Hordei Germinatus (parched) 1-2 part, Rhizoma Pinelliae 1-1.5 part, Radix Codonopsis 1-1.5 part.
Above-mentioned Colla Corii Asini also can be replaced with 0.5-1 part Cornu Cervi.
The present invention's each component preferred weight part is: Radix Rhodiolae 3 parts, Radix Ginseng 2 parts, the Radix Astragali 3 parts, Radix Ginseng 2 parts, the Rhizoma Atractylodis Macrocephalae 2 parts, 2 parts, Poria, Radix Glycyrrhizae Preparata 2 parts, Radix Angelicae Sinensis 2 parts, Rhizoma Chuanxiong 2 parts, Ganoderma 2 parts, 2 parts, Radix Rehmanniae Preparata, 2 parts, Colla Corii Asini, Fructus Lycii 3 parts, Rhizoma Polygonati 3 parts, Endothelium Corneum Gigeriae Galli 1 part, Fructus Hordei Germinatus (parched) 1 part, the Rhizoma Pinelliae 1 part, Radix Codonopsis 1 part.
Above-mentioned Colla Corii Asini can use Colla cornus cervi 1 part replacement.
Chinese medicine composition of the present invention is decoction, above-mentioned raw material of Chinese medicine is got 10 grams every part for potion, weighs decocting, every day potion, 7 dose of one course for the treatment of.
Chinese medicine composition of the present invention also can be made by traditional method and take liquid, granule, fluid extract or pill day.
Above-mentioned each component pharmacological action is analyzed: the negative and positive of Radix Rhodiolae, Radix Ginseng, Fructus Ligustri Lucidi, Herba Ecliptae, the common the kidney invigorating of Rhizoma Polygonati, Radix Ginseng, Poria, the Rhizoma Atractylodis Macrocephalae, Radix Angelicae Sinensis, Radix Rehmanniae Preparata, Rhizoma Chuanxiong, Ganoderma, Radix Glycyrrhizae Preparata, the Radix Astragali, Colla Corii Asini, Fructus Lycii and eight delicacies Tonga Radix Astragali Colla Corii Asini, Fructus Lycii qi and blood tonifying is held concurrently and can be invigorated blood circulation, separately add Radix Codonopsis, the Rhizoma Pinelliae, Fructus Amomi, Endothelium Corneum Gigeriae Galli, Fructus Hordei Germinatus eliminates indigestion and phlegm, make its tonify without causing stagnation.
The present invention is leukopenic theoretical foundation after treating radiotherapy: radiotherapy belongs to " attacking method " category of motherland's medical science " treating the poisonous disease with poisonous drugs ".Though radiotherapy likely makes body reach " heresy is gone just from peace ", one of its modal toxicity is bone marrow depression, and radiotherapy medicine is as poisonous product, sending an expedition against in body while cancer poison, more increased the weight of the damage of QI and blood internal organs, especially spleen kidney two is dirty, cause positive QI consumed wound, the biochemical weary source of QI and blood.Main manifestations is all empty not enough clinically, and resistance declines.As " Plain Questions logical comments deficiency and excess opinion " is said: " lack of vital essence resulting in deficiency syndrome ", " Required Readings for Medical Professionals asthenia " is said: " do not belong to gas and namely belong to blood, outward not here the vital organs of the human body can.And solely lift spleen kidney person, water is the source of all things on earth, and soil is the mother of all things on earth, two dirty peaces and, all control all over the body, hundred diseases are not given birth to ".According to above principle, our prescription feature is: (1) kidney tonifying, essence replenishing is main, to agitate bone marrow hematogenesis, and warm spleen sun transporting; (2) spleen benefiting and replenishing qi and blood is auxiliary, makes the source of QI and bloodization life sufficient; (3) logical benefit combines, tonify without causing stagnation.Modern pharmacological research also demonstrate that these medicines have stimulation bone marrow hematogenesis, promote leukocytic effect.
The present invention is on the basis of the special side treating the leukopenia that a variety of causes causes for many years, and combination with radiotherapeutic develops the hurtful pathological characteristic of human body.
Decoction is named as by the present invention " celestial clever raw plain soup ", for preventing and treating leukopenia 1,000 many cases that radiotherapy causes.From year June in January, 2007 to 2010, inventor is leukopenic patient after Shandong Tumor Hospital applies the present invention to various tumor radiotherapy, and did and observe in detail and have keeper 386 example, average medication natural law 10 days, effective percentage reaches 97%.Therefore, it is high that we have effective percentage, low relative to Western medicine (granulocyte colony-stimulating factor) expense, and be not easy the advantages such as falling, clinic application and popularization.
Above-mentioned 386 routine patients, point prevention group and treatment group 2 groups carry out clinical observation:
1, prevention group 143 people: rise plain soup, every day 1 dose to the celestial spirit of son, starting to take medicine for first 3 days in radiotherapy, 3 weeks is a course for the treatment of.Observe the situation of change of leukocyte (WBC) before and after treatment.
2, treatment group 243 people: WBC<3.50 X 10 after radiotherapy 9start application during/L, rise plain soup, every day 1 dose to the celestial spirit of son.Within 2 weeks, be a course for the treatment of, observe the situation of change of leukocyte (WBC) before and after treatment.
The results detailed in Table 1:
? Number Effective people % Effective people % Invalid people % Effective percentage %
Prevention group 143 129（90.2） 12（8.2） 2（1.4） 98.6
Treatment group 243 198（81.5） 19（7.8） 13（5.3） 94.7
Table 1 respectively group observes case load and effective percentage:
More than observe and describe we to have effective percentage for leukopenia after radiotherapy high, low relative to Western medicine (leukocyte colony stimulating factor) expense, and after application, leukocyte is not easy the advantages such as falling.
Detailed description of the invention
Embodiment 1
Raw material is taken: Radix Rhodiolae 150g, Radix Ginseng 90g, Fructus Ligustri Lucidi 90g, Herba Ecliptae 90g according to following weight proportioning, Fructus Lycii 150g, Rhizoma Polygonati 150g, the Radix Astragali 160 g, Radix Ginseng 90g, Poria 100 g, Rhizoma Atractylodis Macrocephalae 100g, Radix Angelicae Sinensis 100g, Radix Rehmanniae Preparata 100g, Rhizoma Chuanxiong g0g, Ganoderma g0g, Fructus Amomi 30g, Colla Corii Asini 100g, Radix Glycyrrhizae Preparata 50g, Endothelium Corneum Gigeriae Galli 50g, Fructus Hordei Germinatus (parched) 50g, Radix Codonopsis 50g, Rhizoma Pinelliae 50g
Preparation method: above medicine first breaks into coarse powder, makes through technical processs such as lixiviate, purification, concentrated, subpackage, sterilizings and takes liquid 1000m1 day, every day 3 times, each 20m1, for clinical practice.
Embodiment 2
Raw material is taken: Radix Rhodiolae 3 parts, Radix Ginseng 2 parts, the Radix Astragali 3 parts according to following weight proportioning, Radix Ginseng 2 parts, the Rhizoma Atractylodis Macrocephalae 2 parts, 2 parts, Poria, Radix Glycyrrhizae Preparata 2 parts, Radix Angelicae Sinensis 2 parts, Rhizoma Chuanxiong 2 parts, Ganoderma 2 parts, 2 parts, Radix Rehmanniae Preparata, 2 parts, Colla Corii Asini, Fructus Lycii 3 parts, Rhizoma Polygonati 3 parts, Endothelium Corneum Gigeriae Galli 1 part, Fructus Hordei Germinatus (parched) 1 part, the Rhizoma Pinelliae 1 part, Radix Codonopsis 1 part.
Manufacture method: by the manufacture method of above-mentioned each component according to granule, be made into granule, every day 3 times, each 9 grams, for Clinical practice.
Embodiment 3
Raw material is taken: Radix Rhodiolae 3 parts, Radix Ginseng 2 parts, the Radix Astragali 3 parts according to following weight proportioning, Radix Ginseng 2 parts, the Rhizoma Atractylodis Macrocephalae 2 parts, 2 parts, Poria, Radix Glycyrrhizae Preparata 2 parts, Radix Angelicae Sinensis 2 parts, Rhizoma Chuanxiong 2 parts, Ganoderma 2 parts, 2 parts, Radix Rehmanniae Preparata, 2 parts, Colla Corii Asini, Fructus Lycii 3 parts, Rhizoma Polygonati 3 parts, Endothelium Corneum Gigeriae Galli 1 part, Fructus Hordei Germinatus (parched) 1 part, the Rhizoma Pinelliae 1 part, Radix Codonopsis 1 part.
Manufacture method: by the manufacture method of above-mentioned each component according to fluid extract, be made into fluid extract, every day 3 times, each 10 grams, for Clinical practice.
Embodiment 4
Raw material is taken: Radix Rhodiolae 30g, Radix Ginseng 15g, Radix Astragali 30g according to following weight proportioning, Radix Ginseng 15g, Rhizoma Atractylodis Macrocephalae 15g, Poria 20g, Radix Glycyrrhizae Preparata 15g, Radix Angelicae Sinensis 15g, Rhizoma Chuanxiong 15g, Ganoderma 15g, Radix Rehmanniae Preparata 15g, Colla Corii Asini 20g, Fructus Lycii 30g, Rhizoma Polygonati 30g, Endothelium Corneum Gigeriae Galli lOg, Fructus Hordei Germinatus (parched) lOg, Rhizoma Pinelliae lOg, Radix Codonopsis 100g.
Preparation method: be 1 feed ration by said medicine.Beating powder except Colla Corii Asini explodes outside the pale of civilization, all the other each medicines mixing, routinely after herbal decoction decocting with Colla Corii Asini with take, every day, potion, point took for 2 times sooner or later, 7 dose of one course for the treatment of.
In above-mentioned 4 embodiments, also can replace Colla Corii Asini with Colla cornus cervi, consumption reduces by half, and can add 2 parts, the Radix Rehmanniae, the Rhizoma Anemarrhenae 2 parts, help fire with anti-robbery the moon when deficiency of both YIN and YANG or the obvious person of the deficiency of YIN replace Colla Corii Asini with Colla cornus cervi.This example is also within scope.
Lift two below again and take decoction with day of the present invention, prevent leukopenic example, prove curative effect of the present invention further.
Case one: Lee XX, man, 52 years old, the court's radiotherapy one section inpatient.After esophageal patient's cancer radiotherapy 3 cycle radiotherapy 20 days.Repeatedly there is leukopenia in radiation period, repeatedly subcutaneous injection granulocyte colony-stimulating factor, can rise to normal in the past, and this injection 7 days leukocyte are still low, cannot carry out the radiotherapy of the 4th cycle.Routine blood test: WBC, 2. 6 X 10 9/ L, HGB10. 6g/L, platelet is normal.Disease is seen: malaise, complexion are shaken white, soreness of the waist and knees, poor appetite, and day is light dull, day thirsty desire for hot drinks, pale tongue is dark, and white and thin fur, deep pulse is thin and delicate.Chinese medical discrimination belongs to asthenia of both the spleen and kidney, insufficiency of vital energy and blood.
Taste is added: Radix Rhodiolae 30g, Radix Ginseng 15g, Radix Astragali 30g with decoction of the present invention, Radix Ginseng 15g, Rhizoma Atractylodis Macrocephalae 15g, Poria 20g, Radix Glycyrrhizae Preparata 15g, Radix Angelicae Sinensis 15g, Rhizoma Chuanxiong 15g, Ganoderma 15g, Radix Rehmanniae Preparata 15g, Colla cornus cervi 10g(friedization), Fructus Lycii 30g, Rhizoma Polygonati 30g, Endothelium Corneum Gigeriae Galli lOg, Fructus Hordei Germinatus (parched) lOg, Rhizoma Pinelliae lOg, Radix Codonopsis lOg.Every agent is beaten powder and is exploded outside the pale of civilization, all the other each medicines mixing except Colla cornus cervi, routinely after herbal decoction decocting with Colla cornus cervi with take, every day 1 is secondary, point sooner or later takes for 2 times.
Take medicine after 5 doses, check routine blood test: WBC, 3.9 X 10 9/ L, HGB112Xg/L.The radiotherapy of the 4th cycle is carried out after drug withdrawal.Continue after radiotherapy terminates to take medicine-feeding 2 weeks, check hemogram is normal.
Case two: section xx, man, 54 years old, two section inpatients were put in the court.After Radiotherapy of Esophageal Cancer, radiotherapy 3 weeks after dates 21 days, cytopenia.WBC<2.5 X 109/L, HGB150g/L, PLT74 X 109/L, disease is seen: slightly weak, sore waist and aching in the waist and the back, shallow complexion, and day does not do, desire for hot drinks, and two more adjust, the light red few tongue of body of the tongue, thready and weak pulse.Disease belongs to asthenia of both the spleen and kidney, insufficiency of vital energy and blood.
Add and subtract with decoction of the present invention: Radix Rhodiolae 30g, Radix Ginseng 15g, Radix Astragali 30g, Radix Ginseng 15g, Rhizoma Atractylodis Macrocephalae 15g, Poria 20g, Radix Glycyrrhizae Preparata 15g, Radix Angelicae Sinensis 15g, Rhizoma Chuanxiong 15g, Ganoderma 15g, Radix Rehmanniae Preparata 15g, Colla Corii Asini 20g (friedization), Fructus Lycii 30g, Rhizoma Polygonati 30g, Endothelium Corneum Gigeriae Galli 15g, Fructus Hordei Germinatus (parched) 15g, Rhizoma Pinelliae 15g, Radix Codonopsis 12g.Every agent is beaten powder and is exploded outside the pale of civilization, all the other each medicines mixing except Colla Corii Asini, routinely after herbal decoction decocting with Colla Corii Asini with take, every day 1 is secondary, divides 2 times.Take medicine after 4 doses, check routine blood test: WBC<4. 6 X 109/L, PLT9g X 109/L.The radiotherapy of the 4th cycle is carried out after drug withdrawal.Continue after radiotherapy terminates to take medicine-feeding 2 weeks, check hemogram is normal.

Claims (6)

1. cause a leukopenic Chinese medicine composition for preventing and treating radiotherapy, it is characterized in that, it is made up of the raw material of Chinese medicine of following weight portion: Radix Rhodiolae 2-3 part, Radix Ginseng 1-2 part, Radix Astragali 2-3 part, Radix Ginseng 1-2 part, Rhizoma Atractylodis Macrocephalae 1-2 part, Poria 2-3 part, Radix Glycyrrhizae Preparata 1-2 part, Radix Angelicae Sinensis 1-2 part, Rhizoma Chuanxiong 1-2 part, Ganoderma 1-2 part, Radix Rehmanniae Preparata 1-2 part, Colla Corii Asini 1-2 part, Fructus Lycii 2-3 part, Rhizoma Polygonati 2-3 part, Endothelium Corneum Gigeriae Galli 1-2 part, Fructus Hordei Germinatus (parched) 1-2 part, Rhizoma Pinelliae 1-1.5 part, Radix Codonopsis 1-1.5 part.
2. Chinese medicine composition according to claim 1, is characterized in that, it is made up of the raw material of Chinese medicine of following weight portion: Radix Rhodiolae 3 parts, Radix Ginseng 2 parts, the Radix Astragali 3 parts, Radix Ginseng 2 parts, the Rhizoma Atractylodis Macrocephalae 2 parts, 2 parts, Poria, Radix Glycyrrhizae Preparata 2 parts, Radix Angelicae Sinensis 2 parts, Rhizoma Chuanxiong 2 parts, Ganoderma 2 parts, 2 parts, Radix Rehmanniae Preparata, 2 parts, Colla Corii Asini, Fructus Lycii 3 parts, Rhizoma Polygonati 3 parts, Endothelium Corneum Gigeriae Galli 1 part, Fructus Hordei Germinatus (parched) 1 part, the Rhizoma Pinelliae 1 part, Radix Codonopsis 1 part.
3. Chinese medicine composition according to claim 1 and 2, is characterized in that, the described Colla Corii Asini Colla cornus cervi of the amount of reducing by half is replaced.
4. Chinese medicine composition according to claim 1, is characterized in that, it is by the decoction become with the raw material of Chinese medicine decocting of subsequent dose: Radix Rhodiolae 30g, Radix Ginseng 15g, Radix Astragali 30g, Radix Ginseng 15g, Rhizoma Atractylodis Macrocephalae 15g, Poria 20g, Radix Glycyrrhizae Preparata 15g, Radix Angelicae Sinensis 15g, Rhizoma Chuanxiong 15g, Ganoderma 15g, Radix Rehmanniae Preparata 15g, Fructus Lycii 30g, Rhizoma Polygonati 30g, Endothelium Corneum Gigeriae Galli lOg, Fructus Hordei Germinatus (parched) lOg, Rhizoma Pinelliae lOg, Radix Codonopsis lOg; Separately add, Colla Corii Asini 20g mixes with above-mentioned decoction after beating powder friedization.
5. Chinese medicine composition according to claim 4, is characterized in that, described Colla Corii Asini Colla cornus cervi lOg replaces.
6. Chinese medicine composition according to claim 1 and 2, is characterized in that, it makes oral liquid, granule, fluid extract or pill one wherein by Chinese medicine processing method.
CN201410563172.XA 2014-10-22 2014-10-22 Traditional Chinese medicine combination for preventing and curing leucopenia caused by radiotherapy Pending CN104258203A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201410563172.XA CN104258203A (en) 2014-10-22 2014-10-22 Traditional Chinese medicine combination for preventing and curing leucopenia caused by radiotherapy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201410563172.XA CN104258203A (en) 2014-10-22 2014-10-22 Traditional Chinese medicine combination for preventing and curing leucopenia caused by radiotherapy

Publications (1)

Publication Number Publication Date
CN104258203A true CN104258203A (en) 2015-01-07

Family

ID=52149860

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201410563172.XA Pending CN104258203A (en) 2014-10-22 2014-10-22 Traditional Chinese medicine combination for preventing and curing leucopenia caused by radiotherapy

Country Status (1)

Country Link
CN (1) CN104258203A (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104800692A (en) * 2015-04-27 2015-07-29 陶俊荣 Chinese material medicine preparation for alleviating side effects from radiation therapy and preparation method
CN105148039A (en) * 2015-10-28 2015-12-16 冷宁 Traditional Chinese medicine pill used for relieving tumor postradiotherapy reaction and preparation method
CN109157636A (en) * 2018-11-26 2019-01-08 张瑞武 A kind of Chinese medicine composition for rehabilitation after cancer chemotherapy
CN110151965A (en) * 2019-06-18 2019-08-23 张志明 A kind of Chinese medicine composition for treating bone marrow suppression leukopenia after chemotherapy
CN114469859A (en) * 2021-03-19 2022-05-13 山东新时代药业有限公司 Application of ginseng root-strengthening oral liquid in treating leukopenia

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101601835A (en) * 2008-06-13 2009-12-16 北京中泰天和科技有限公司 Tumor post-operation treating medicine and preparation method thereof
CN102058805A (en) * 2010-11-14 2011-05-18 耿平 Oral medicine for preventing and treating leukocytopenia caused by chemotherapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101601835A (en) * 2008-06-13 2009-12-16 北京中泰天和科技有限公司 Tumor post-operation treating medicine and preparation method thereof
CN102058805A (en) * 2010-11-14 2011-05-18 耿平 Oral medicine for preventing and treating leukocytopenia caused by chemotherapy

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104800692A (en) * 2015-04-27 2015-07-29 陶俊荣 Chinese material medicine preparation for alleviating side effects from radiation therapy and preparation method
CN105148039A (en) * 2015-10-28 2015-12-16 冷宁 Traditional Chinese medicine pill used for relieving tumor postradiotherapy reaction and preparation method
CN109157636A (en) * 2018-11-26 2019-01-08 张瑞武 A kind of Chinese medicine composition for rehabilitation after cancer chemotherapy
CN110151965A (en) * 2019-06-18 2019-08-23 张志明 A kind of Chinese medicine composition for treating bone marrow suppression leukopenia after chemotherapy
CN110151965B (en) * 2019-06-18 2021-09-21 张志明 Traditional Chinese medicine composition for treating myelosuppressive leukopenia after chemotherapy
CN114469859A (en) * 2021-03-19 2022-05-13 山东新时代药业有限公司 Application of ginseng root-strengthening oral liquid in treating leukopenia

Similar Documents

Publication Publication Date Title
CN102058805B (en) Oral medicine for preventing and treating leukocytopenia caused by chemotherapy
JP2004537508A (en) Antitumor drug
CN104258203A (en) Traditional Chinese medicine combination for preventing and curing leucopenia caused by radiotherapy
CN101234181B (en) Medicament for preventing and treating leukopenia used in tumor radiotherapy and chemotherapy course
CN102579803B (en) Medicine for treating post-chemotherapy leucopenia and preparation method thereof
CN111514266B (en) Pharmaceutical composition for improving curative effect of paclitaxel rhythm chemotherapy on gastric cancer metastasis and preparation method and application thereof
CN103550506A (en) Traditional Chinese medicine composition cooperatively used in radiotherapy
CN102784292B (en) Constitution consolidating and life prolonging medicinal preparation and preparation method thereof
CN104173950A (en) Chinese herbal medicine composition for treating prostatic cancer
CN101912596B (en) Medicament for treating allergic rhinitis and preparation method thereof
CN101979013B (en) Traditional Chinese medicine for treating leukemia
CN101804175B (en) Anti-cancer Chinese medicinal powder and preparation method thereof
CN109939191A (en) Chinese medicine composition, preparation method and the application of bone marrow suppression after a kind of antagonism chemotherapy of tumors
CN102872385B (en) Compound Chinese medicinal composition for treating advanced gastric cancer and preparation method and application thereof
CN105362904A (en) Qi tonifying and blood nourishing traditional Chinese medicinal pill and preparation method thereof
CN104140916A (en) Traditional Chinese medicine smilacina japonica liquor
CN106511915A (en) Applications of compound traditional Chinese medicinal composition in preparing medicines for inhibiting skin melanoma lung metastasis
CN103191267B (en) Traditional Chinese medicine composition for treating liver cancers
CN102078600A (en) Anti-cancer compound ganoderma composition, application thereof and pharmaceutical composition containing same
CN105435206A (en) Traditional Chinese medicine preparation for preventing and treating bone marrow suppression after radiotherapy and chemotherapy
CN104435545A (en) Traditional Chinese medicine preparation for treating leucopenia caused by benzene poisoning
CN102000303B (en) Compound traditional Chinese medicine preparation for suppressing tumors
CN102068604A (en) Modified angelica sinensis blood enriching preparation and application and preparation method thereof
CN1194717C (en) Snake poison capsule for treating lung cancer and its preparation method
CN101229272A (en) Medicine compounds for increasing immunizing-power, preparing method and applications thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20150107